Agfa-Gevaert appoints Luc Thijs as President of Agfa HealthCare

Thu Feb 17, 2011 7:00am EST

* Reuters is not responsible for the content in this press release.

Mortsel, Belgium - February 17, 2011 - 1:00 p.m. CET

 

During its meeting of February 15, 2011, the Board of Directors of Agfa-Gevaert has accepted the recommendation from CEO Christian Reinaudo to appoint Luc Thijs as President of the Agfa HealthCare business group and member of the Group's Executive Committee, effective April 1, 2011. Luc Thijs succeeds Christian Reinaudo who, until now, combined his role of CEO of the Agfa-Gevaert Group with his former position of President Agfa HealthCare.

 

Christian Reinaudo, CEO of Agfa-Gevaert, stated: "In Luc Thijs we have found the combination of strong managerial qualities and a deep knowledge of both the healthcare industry and the Agfa HealthCare business group. Over the past years, the Agfa HealthCare business group has been reorganized and streamlined. It has now a clear strategy and an efficient organization at its disposal to deal with the many challenges of this industry. With Luc leading the HealthCare operations, I will be fully able to focus on my role of CEO of the Agfa-Gevaert Group and the implementation of our growth strategy."

 

CV Luc Thijs

Luc Thijs (46) is Belgian. He obtained a Masters degree in commercial and consular sciences (1987), as well as a Masters degree in commercial and financial sciences (1988) at the School of Economics (EHL) in Diepenbeek, Belgium. In 2004 he complemented his education with the Advanced Management Program at Insead in Paris.

After a brief period at Bekaert Textiles, he started his career at Agfa Gevaert's Medical Division in 1990. He took up consecutive general management roles for Agfa HealthCare in Asia Pacific, Latin America and Italy.

As from 2006, he was in charge of Agfa HealthCare's global Imaging Division.

Since 2009, he led Agfa HealthCare's Growth Markets region, comprising Asia Pacific, Latin America, Africa, the Middle East and the CIS countries.

 

 

About Agfa
The Agfa-Gevaert Group is one of the world's leading companies in imaging and information technology. Agfa develops, manufactures and markets analog and digital systems for the printing industry (Agfa Graphics), for the healthcare sector (Agfa HealthCare), and for specific industrial applications (Agfa Materials). Agfa is headquartered in Mortsel, Belgium. The company is present in 40 countries and has agents in another 100 countries around the globe. The Agfa-Gevaert Group achieved a turnover of 2,755 million euro in 2009.

 

About Agfa HealthCare
Agfa HealthCare, a member of the Agfa-Gevaert Group, is a leading global provider of diagnostic imaging and healthcare IT solutions.  The company has nearly a century of healthcare experience and has been a pioneer on the healthcare IT market since the early 1990's.  Today Agfa HealthCare designs, develops and delivers state-of-the-art systems for capturing, managing and processing diagnostic images and clinical/administrative information for hospitals and healthcare facilities, as well as contrast media solutions to enable effective medical imaging results. The company has sales offices and agents in over 100 markets worldwide. Sales for Agfa HealthCare in 2009 were 1,178 million euro.  For more information on Agfa HealthCare, please visit www.agfahealthcare.com.

 

 

Contacts Agfa-Gevaert

 

Viviane Dictus
Director Corporate Communication
T: +32 (0) 3 444 71 24
E: viviane.dictus@agfa.com

 

Johan Jacobs
Corporate Press Relations Manager
T +32 (0)3 444 80 15
E: johan.jacobs@agfa.com

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Agfa-Gevaert via Thomson Reuters ONE


HUG#1490023


Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.